Advanced search
Publication Cover
Bioanalysis Volume 1, 2009 - Issue 9
Submit an article Journal homepage
226
Views
0
CrossRef citations to date
0
Altmetric
Review

Metabonomic Studies of Schizophrenia and Psychotropic Medications: Focus on Alterations in CNS Energy Homeostasis

Dan Ma1 Institute of Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK. [email protected]View further author information
,
Paul C Guest2 [email protected]View further author information
&
Sabine Bahn3 [email protected]Correspondence[email protected]
View further author information
Pages 1615-1626 | Published online: 07 Dec 2009

Bibliography

  • Lang UE , PulsI, MullerDJ, Strutz-SeebohmN, GallinatJ. Molecular mechanisms of schizophrenia. Cell Physiol. Biochem. 20(6), 687–702 (2007).
  • Purcell SM , WrayNR, StoneJLet al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature460(7256), 748–752 (2009).
  • Nikolaus S , AntkeC, MullerHW. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav. Brain Res. 204(1), 32–66 (2009).
  • Howes OD , KapurS. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr. Bull. 35(3), 549–562 (2009).
  • Karlsgodt KH , SunD, JimenezAMet al. Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia. Dev. Psychopathol. 20(4), 1297–1327 (2008).
  • Fatemi SH , FolsomTD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 35(3), 528–548 (2009).
  • Davis KL , StewartDG, FriedmanJIet al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry60(5), 443–456 (2003).
  • Meyer U , FeldonJ, YeeBK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr. Bull. 35(5), 959–972 (2008).
  • Chubb JE , BradshawNJ, SoaresDC, PorteousDJ, MillarJK. The DISC locus in psychiatric illness. Mol. Psychiatry13(1), 36–64 (2008).
  • Schumacher J , LajeG, Abou Jamra Ret al. The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Hum. Mol. Genet. 18(14), 2719–2727 (2009).
  • Wong AH , Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev. 27(3), 269–306 (2003).
  • Thomas EA . Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol. Neurobiol. 34(2), 109–128 (2006).
  • Prabakaran S , SwattonJE, RyanMMet al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry9(7), 684–697, 643 (2004).
  • Iwamoto K , KatoT. Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist12(4), 349–361 (2006).
  • Schreurs V , VancampfortD. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry8(1), 15–22 (2009).
  • Rezin GT , CardosoMR, GoncalvesCLet al. Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem. Int. 53(6–8), 395–400 (2008).
  • Rezin GT , AmboniG, ZugnoAI, QuevedoJ, StreckEL. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 34(6), 1021–1029 (2009).
  • Martins-de-Souza D , GattazWF, SchmittAet al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J. Psychiatr. Res. 43(11), 978–986 (2009).
  • Ma D , ChanMK, LockstoneHEet al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J. Proteome Res. 8(7), 3284–3297 (2009).
  • Kaddurah-Daouk R , McEvoyJ, BaillieRAet al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry12(10), 934–945 (2007).
  • McLoughlin GA , MaD, TsangTMet al. Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J. Proteome Res. 8(4), 1943–1952 (2009).
  • Quinones MP , Kaddurah-DaoukR. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35(2), 165–176 (2009).
  • Schwarz E , BahnS. Biomarker discovery in psychiatric disorders. Electrophoresis29(13), 2884–2890 (2008).
  • Ben-Shachar D . Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J. Neurochem. 83(6), 1241–1251 (2002).
  • Ben-Shachar D , BonneO, ChisinRet al. Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study. Prog. Neuropsychopharmacol. Biol. Psychiatry31(4), 807–813 (2007).
  • Ben-Shachar D , ZukR, GazawiH, LjubuncicP. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem. Pharmacol. 67(10), 1965–1974 (2004).
  • Dror N , KleinE, KarryRet al. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol. Psychiatry7(9), 995–1001 (2002).
  • Uranova N , OrlovskayaD, VikhrevaOet al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 55(5), 597–610 (2001).
  • Prince JA , BlennowK, GottfriesCG, KarlssonI, OrelandL. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology21(3), 372–379 (1999).
  • Maurer I , ZierzS, MollerH. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 48(1), 125–136 (2001).
  • Fuke S , KametaniM, KatoT. Quantitative analysis of the 4977-bp common deletion of mitochondrial DNA in postmortem frontal cortex from patients with bipolar disorder and schizophrenia. Neurosci. Lett. 439(2), 173–177 (2008).
  • Wood SJ , YucelM, PantelisC, BerkM. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann. Acad. Med. Singapore38(5), 396–396 (2009).
  • Chua SE , McKennaPJ. Schizophrenia – a brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br. J. Psychiatry166(5), 563–582 (1995).
  • Andreasen NC , O’LearyDS, FlaumMet al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet349(9067), 1730–1734 (1997).
  • Buchsbaum MS , HazlettEA. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr. Bull. 24(3), 343–364 (1998).
  • Kegeles LS , HumaranTJ, MannJJ. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol. Psychiatry44(6), 382–398 (1998).
  • Fujimoto T , NakanoT, TakanoT, HokazonoY, AsakuraT, TsujiT. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatr. Scand. 86(6), 455–462 (1992).
  • Volz HR , RiehemannS, MaurerIet al. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study. Biol. Psychiatry47(11), 954–961 (2000).
  • Burbaeva G , SavushkinaOK, BokshaIS. Creatine kinase BB in brain in schizophrenia. World J. Biol. Psychiatry4(4), 177–183 (2003).
  • Dean B , BoerS, GibbonsA, MoneyT, ScarrE. Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr. Opin. Psychiatry22(2), 154–160 (2009).
  • Altar CA , VawterMP, GinsbergSD. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology34(1), 18–54 (2009).
  • Middleton FA , MirnicsK, PierriJN, LewisDA, LevittP. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 22(7), 2718–2729 (2002).
  • Vawter MP , BarrettT, CheadleCet al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 55(5), 641–650 (2001).
  • Stone WS , FaraoneSV, SuJ, TarboxSI, Van Eerdewegh P, Tsuang MT. Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127B(1), 5–10 (2004).
  • Stone M , Hartmann-PetersenR, SeegerM, Bech-OtschirD, WallaceM, GordonC. Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast. J. Mol. Biol. 344(3), 697–706 (2004).
  • Winton-Brown TT , KapurS. Neuroimaging of schizophrenia: what it reveals about the disease and what it tells us about a patient. Ann. Acad. Med. Singapore38(5), 433–433 (2009).
  • Dager SR , CorriganNM, RichardsTL, PosseS. Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top Magn. Reson. Imaging19(2), 81–96 (2008).
  • Fukumoto-Motoshita M , MatsuuraM, OhkuboTet al. Hyperfrontality in patients with schizophrenia during saccade and antisaccade tasks: a study with fMRI. Psychiatry Clin. Neurosci. 63(2), 209–217 (2009).
  • Pieczenik SR , NeustadtJ. Mitochondrial dysfunction and molecular pathways of disease. Exp. Mol. Pathol. 83(1), 84–92 (2007).
  • Bubenikova-Valesova V , HoracekJ, VrajovaM, HoschlC. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev. 32(5), 1014–1023 (2008).
  • Mouri A , NodaY, EnomotoT, NabeshimaT. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 51(2–4), 173–184 (2007).
  • Morris BJ , CochranSM, PrattJA. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5(1), 101–106 (2005).
  • de Oliveira L , DosSSCM, BortolinTet al. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry33(6), 1003–1008 (2009).
  • Rezin GT , GoncalvesCL, DaufenbachJFet al. Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress. Brain Res. Bull. 79(6), 418–421 (2009).
  • Paulson L , MartinP, PerssonAet al. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 71(4), 526–533 (2003).
  • Paulson L , MartinP, NilssonCLet al. Comparative proteome analysis of thalamus in MK-801-treated rats. Proteomics4(3), 819–825 (2004).
  • Paulson L , MartinP, LjungE, BlennowK, DavidssonP. Effects on rat thalamic proteome by acute and subchronic MK-801-treatment. Eur. J. Pharmacol. 505(1–3), 103–109 (2004).
  • Cochran SM , KennedyM, McKercharCE, StewardLJ, PrattJA, MorrisBJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology28(2), 265–275 (2003).
  • Willis CL , RayDE. Antioxidants attenuate MK-801-induced cortical neurotoxicity in the rat. Neurotoxicology28(1), 161–167 (2007).
  • Harris LW , LockstoneHE, KhaitovichP, WeickertCS, WebsterMJ, BahnS. Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Med. Genomics2, 28 (2009).
  • Ji B , LaY, GaoLet al. A Comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J. Proteome Res. 8(7), 3633–3641 (2009).
  • Parikh V , KhanMM, MahadikSP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 37(1), 43–51 (2003).
  • Fatemi SH . Olanzapine increases glucogenesis by multiple pathways in brain and muscle. Mol. Psychiatry11(6), 524–525 (2006).
  • Fatemi SH , ReutimanTJ, FolsomTDet al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology31(9), 1888–1899 (2006).
  • Stephan KE , FristonKJ, FrithCD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr. Bull. 35(3), 509–527 (2009).
  • Lau CG , ZukinRS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8(6), 413–426 (2007).
  • Seeman P . Glutamate and dopamine components in schizophrenia. J. Psychiatry Neurosci. 34(2), 143–149 (2009).
  • Mattson MP , GleichmannM, ChengA. Mitochondria in neuroplasticity and neurological disorders. Neuron60(5), 748–766 (2008).
  • Ben-Shachar D , LaifenfeldD. Mitochondria, synaptic plasticity and schizophrenia. Int. Rev. Neurobiol. 59, 273–296 (2004).
  • Jarskog LF , GilmoreJH, SelingerES, LiebermanJA. Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry48(7), 641–650 (2000).
  • Doyle CA , SlaterP. Application of [3H]L-N(G)-nitro-arginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. Neurosci. Lett. 202(1–2), 49–52 (1995).
  • Mahadik SP , SchefferRE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids55(1–2), 45–54 (1996).
  • Mahadik SP , MukherjeeS. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 19(1), 1–17 (1996).
  • Kaddurah-Daouk R , KrishnanKR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology34(1), 173–186 (2009).
  • Bassett DS , BullmoreET. Human brain networks in health and disease. Curr. Opin. Neurol. 22(4), 340–347 (2009).
  • Noble JM , ScarmeasN. Application of pet imaging to diagnosis of Alzheimer’s disease and mild cognitive impairment. Int. Rev. Neurobiol. 84, 133–149 (2009).
  • Nikolaus S , AntkeC, MullerHW. In vivo imaging of synaptic function in the central nervous system I. Movement disorders and dementia. Behav. Brain Res. 204(1), 1–31 (2009).
  • Nicholson JK , LindonJC, HolmesE. ‘Metabonomics‘: understanding the metabolic responses of living systems to pathophysiological sti muli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica29(11), 1181–1189 (1999).
  • Tsang TM , GriffinJL, HaseldenJ, FishC, HolmesE. Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy. Magn. Reson. Med. 53(5), 1018–1024 (2005).
  • Holmes E , TsangTM, HuangJTet al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3(8), e327 (2006).
  • Tsang TM , HuangJT, HolmesE, BahnS. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J. Proteome Res. 5(4), 756–760 (2006).
  • Huang JT , LewekeFM, TsangTMet al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE2(1), e756 (2007).
  • Newcomer JW , CraftS, FucetolaRet al. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr. Bull. 25(2), 321–335 (1999).
  • Park IH , KimJJ, ChunJet al. Medial prefrontal default-mode hypoactivity affecting trait physical anhedonia in schizophrenia. Psychiatry Res. 171(3), 155–165 (2009).
  • Wood SJ , BergerGE, WellardRMet al. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis. Schizophr. Res. 102(1–3), 163–170 (2008).
  • Molina V , SoleraS, SanzJet al. Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia. Psychiatry Res. 173(2), 88–93 (2009).
  • Ohrmann P , SiegmundA, SuslowTet al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 73(2–3), 153–157 (2005).
  • Ohrmann P , SiegmundA, SuslowTet al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatr. Res. 41(8), 625–634 (2007).
  • Tsai SJ . Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med. Sci. Monit. 11(9), HY39–HY45 (2005).
  • Tkachev D , MimmackML, HuffakerSJ, RyanM, BahnS. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int. J. Neuropsychopharmacol. 10(4), 557–563 (2007).
  • Theberge J , BarthaR, DrostDJet al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry159(11), 1944–1946 (2002).
  • van Elst LT , ValeriusG, BuchertMet al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry58(9), 724–730 (2005).
  • Halim ND , LipskaBK, HydeTMet al. Increased lactate levels and reduced pH in postmortem brains of schizophrenics: medication confounds. J. Neurosci. Methods169(1), 208–213 (2008).
  • De Keyser J , MostertJP, KochMW. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci. 267(1–2), 3–16 (2008).
  • Khaitovich P , LockstoneHE, WaylandMTet al. Metabolic changes in schizophrenia and human brain evolution. Genome Biol. 9(8), R124 (2008).
  • Moffett JR , RossB, ArunP, MadhavaraoCN, NamboodiriAM. N acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81(2), 89–131 (2007).
  • Chang L , FriedmanJ, ErnstT, ZhongK, TsopelasND, DavisK. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol. Psychiatry62(12), 1396–1404 (2007).
  • Atmaca M , YildirimH, OzdemirH, OgurE, TezcanE. Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine. Psychol. Med. 37(1), 121–129 (2007).
  • Abbott C , BustilloJ. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr. Opin. Psychiatry19(2), 135–139 (2006).
  • Sigmundsson T , MaierM, TooneBKet al. Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 64(1), 63–71 (2003).
  • Magistretti PJ . Neuron–glia metabolic coupling and plasticity. J. Exp. Biol. 209(Pt 12), 2304–2311 (2006).
  • Fillenz M . The role of lactate in brain metabolism. Neurochem. Int. 47(6), 413–417 (2005).
  • Escartin C , ValetteJ, LebonV, BonventoG. Neuron–astrocyte interactions in the regulation of brain energy metabolism: a focus on NMR spectroscopy. J. Neurochem. 99(2), 393–401 (2006).
  • Schousboe A , BakLK, SickmannHM, SonnewaldU, WaagepetersenHS. Energy substrates to support glutamatergic and GABAergic synaptic function: role of glycogen, glucose and lactate. Neurotox. Res. 12(4), 263–268 (2007).
  • Sarramea Crespo F , LuqueR, PrietoDet al. Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 258(7), 394–401 (2008).
  • Wood SJ , BergerGE, WellardRMet al. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis. Schizophr. Res. 102(1–3), 163–170 (2008).
  • Ongur D , PrescotAP, JensenJE, CohenBM, RenshawPF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 172(1), 44–48 (2009).
  • Gualano B , ArtioliGG, PoortmansJR, Lancha Junior AH. Exploring the therapeutic role of creatine supplementation. Amino Acids (2009) (Epub ahead of print).
  • Rae C , Moussa Cel H, Griffin JLet al. A metabolomic approach to ionotropic glutamate receptor subtype function: a nuclear magnetic resonance in vitro investigation. J. Cereb. Blood Flow Metab. 26(8), 1005–1017 (2006).
  • Iltis I , KoskiDM, EberlyLEet al. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized 1H MRS study. NMR Biomed. 22(7), 737–744 (2009).
  • Buckley PF . Update on the treatment and management of schizophrenia and bipolar disorder. CNS Spectr. 13(2 Suppl. 1), 1–10; quiz 11–12 (2008).
  • De Oliveira IR , JuruenaMF. Treatment of psychosis: 30 years of progress. J. Clin. Pharm. Ther. 31(6), 523–534 (2006).
  • Ashby CR Jr , WangRY. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse24(4), 349–394 (1996).
  • Lublin H , EberhardJ, LevanderS. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. 20(4), 183–198 (2005).
  • Stone JM , PilowskyLS. Novel targets for drugs in schizophrenia. CNS Neurol. Disord. Drug Targets6(4), 265–272 (2007).
  • Horacek J , Bubenikova-ValesovaV, KopecekMet al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs20(5), 389–409 (2006).
  • Wood M , ReavillC. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin. Investig. Drugs16(6), 771–775 (2007).
  • Szulc A , GalinskaB, TarasowEet al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry38(5), 214–219 (2005).
  • DelBello MP , CecilKM, AdlerCM, DanielsJP, StrakowskiSM. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology31(6), 1264–1273 (2006).
  • Bustillo JR , RowlandLM, JungRet al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology33(10), 2456–2466 (2008).
  • Tayoshi S , SumitaniS, TaniguchiKet al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr. Res. 108(1–3), 69–77 (2009).
  • Olbrich HM , ValeriusG, RuschNet al. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J. Biol. Psychiatry9(1), 59–63 (2008).
  • Vernaleken I , CummingP, GrunderG. Imaging studies – differential action of typical and atypical antipsychotics in a network perspective. Pharmacopsychiatry41(Suppl. 1), S60–S69 (2008).
  • Laron Z . Insulin and the brain. Arch. Physiol. Biochem. 115(2), 112–116 (2009).
  • Reger MA , WatsonGS, GreenPSet al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology70(6), 440–448 (2008).
  • Oja SS , SaransaariP. Pharmacology of taurine. Proc. West Pharmacol. Soc. 50, 8–15 (2007).
  • Yao JK , DoughertyGGJr, ReddyRDet al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry (2009) (Epub ahead of print).
  • Sinclair AJ , ViantMR, BallAKet al. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases – a diagnostic tool? NMR Biomed . (2009) (Epub ahead of print).
  • Nebert DW , VesellES. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol. Sci. 27(11), 580–586 (2006).
  • Martinez-Forero I , PelaezA, VillosladaP. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin. Pharmacother. 9(17), 3053–3067 (2008).
  • Villoslada P , SteinmanL, BaranziniSE. Systems biology and its application to the understanding of neurological diseases. Ann. Neurol. 65(2), 124–139 (2009).
  • Giegling I , HartmannAM, GeniusJ, BenninghoffJ, MollerHJ, RujescuD. Systems biology and complex neurobehavioral traits. Pharmacopsychiatry41(Suppl. 1), S32–S36 (2008).
  • Quintana FJ , FarezMF, WeinerHL. Systems biology approaches for the study of multiple sclerosis. J. Cell Mol. Med. 12(4), 1087–1093 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.